Portal de Periódicos da CAPES

Hypoglycemia and glucose counterregulation in normal and insulin‐dependent diabetic subjects

1988; Wiley; Volume: 4; Issue: 1 Linguagem: Inglês

10.1002/dmr.5610040108

1099-0895

Stephanie A. Amiel, William V. Tamborlane, Luigi Saccà, Robert S. Sherwin,

Diabetes Management and Research

Diabetes/Metabolism ReviewsVolume 4, Issue 1 p. 71-89 Hypoglycemia and Counterregulation Hypoglycemia and glucose counterregulation in normal and insulin-dependent diabetic subjects Stephanie A. Amiel, Stephanie A. Amiel Departments of Medicine and Pediatrics and the Clinical Research Centers of the Yale University School of Medicine, New Haven, ConnecticutSearch for more papers by this authorWilliam V. Tamborlane, William V. Tamborlane Departments of Medicine and Pediatrics and the Clinical Research Centers of the Yale University School of Medicine, New Haven, ConnecticutSearch for more papers by this authorLuigi Saccà, Luigi Saccà Departments of Medicine and Pediatrics and the Clinical Research Centers of the Yale University School of Medicine, New Haven, ConnecticutSearch for more papers by this authorRobert S. Sherwin, Corresponding Author Robert S. Sherwin Departments of Medicine and Pediatrics and the Clinical Research Centers of the Yale University School of Medicine, New Haven, ConnecticutDepartments of Medicine and Pediatrics and the Clinical Research Centers of the Yale University School of Medicine, New Haven, ConnecticutSearch for more papers by this author Stephanie A. Amiel, Stephanie A. Amiel Departments of Medicine and Pediatrics and the Clinical Research Centers of the Yale University School of Medicine, New Haven, ConnecticutSearch for more papers by this authorWilliam V. Tamborlane, William V. Tamborlane Departments of Medicine and Pediatrics and the Clinical Research Centers of the Yale University School of Medicine, New Haven, ConnecticutSearch for more papers by this authorLuigi Saccà, Luigi Saccà Departments of Medicine and Pediatrics and the Clinical Research Centers of the Yale University School of Medicine, New Haven, ConnecticutSearch for more papers by this authorRobert S. Sherwin, Corresponding Author Robert S. Sherwin Departments of Medicine and Pediatrics and the Clinical Research Centers of the Yale University School of Medicine, New Haven, ConnecticutDepartments of Medicine and Pediatrics and the Clinical Research Centers of the Yale University School of Medicine, New Haven, ConnecticutSearch for more papers by this author First published: February 1988 https://doi.org/10.1002/dmr.5610040108Citations: 25AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Tasaka Y, and Sekine M: Levels of pancreatic glucagon, insulin and glucose. Horm Metab Res 7: 205–206, 1975. 2 Sokoloff L: Metabolism of the central nervous system in vivo. In Handbook of Physiology. Section I. Neurophysiology. Waverly Press Inc., Baltimore, MD, 1960, p 1843. 3 Crone C: Facilitated transfer of glucose from blood into brain tissue. J Physiol 181: 103–113, 1965. 4 Marks V: The measurement of blood glucose and the definition of hypoglycemia. Horm Metab Res (Suppl 6): 1–6, 1986. 5 Merimee TJ, Tyson JE: Stabilization of plasma glucose during fasting. Normal variation in two separate studies. N Engl J Med 291: 1275–1278, 1974. 6 McGuire EAH, Helderman JH, Tobin JD, Andres R, and Berman M: Effects of arterial vs venous sampling on analysis of glucose kinetics in man. J Apply Physiol 565–573, 1976. 7 Haymond MW, Kan IE, Clarke WL, Pagliara AS, and Santiago JV: Differences in circulating gluconeogenic substrates during short term fasting in men, women, and children. Metabolism 31: 33–42, 1982. 8 Fajans SS, and Floyd JC: Fasting hypoglycemia in adults. N Engl J Med 294: 766–772, 1976. 9 Whipple AO: Hyperinsulinism in relation to pancreatic tumor. Surgery 16: 289–298, 1944. 10 French EB, and Kilpatrick R: The role of adrenaline in hypoglycaemic reactions in man. Clin Sci Mol Med 14: 639–651, 1955. 11 Schwartz NS, Clutter WE, Shah SD, and Cryer PE: Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest 79: 777–781, 1987. 12 Marks V: Physiological responses to hypoglycemia. In Hypoglycemia, 2nd ed., edited by SV Marks, and F. Clifford Rose Blackwell Scientific Publications, Oxford, England, 1982, 64–65. 13 Hoeldtke RD, Boden G, Shuman CR, and Owen OE: Reduced epinephrine secretion and hypoglycemia unawareness in diabetic autonomic neuropathy. Ann Intern Med 96: 459–462, 1982. 14 White NH, Gingerich RL, Levandoski LA, Cryer PE, and Santiago JV: Plasma pancreatic polypeptide response to insulin-induced hypoglycemia as a marker for defective glucose counterregulation in insulin-dependent diabetes mellitus. Diabetes 34: 870–875, 1984. 15 Arias P, Kemer W, Zier H, Navascues I, and Pfeiffer EF: Incidence of hypoglycemic episodes in diabetic patients under continuous subcutaneous insulin infusion and intensified conventional treatment: assessment by means of semi-ambulatory 24 hr continuous blood glucose monitoring. Diabetes Care 8: 134–140, 1985. 16 Cole RA, Benedict GW, Margolis S, and Kowarski A: Blood glucose monitoring in symptomatic hypoglycemia. Diabetes 25: 984–987, 1976. 17 Lilavivalhana V, Brodows RG, Woolf RD, and Campbell EG: Counterregulatory hormone responses to rapid glucose lowering. Diabetes 28: 873–877, 1979. 18 Santiago JV, Clarke WL, Shah SD, and Cryer PE: Epinephrine, norepinephrine, glucagon and growth hormone release in association with physiological decrements in the plasma glucose concentration in normal and diabetic man. J Clin Endocrinol Metab 51: 877–883, 1980. 19 DeFronzo RA, et al: A test of the hypothesis that the rate of glucose fall triggers a counterregulatory hormone response to hypoglycemia. Diabetes 26: 445–452, 1977. 20 Amiel SA, Simonson DC, Tamborlane WV, DeFronzo RA, and Sherwin RS: The rate of glucose fall does not affect the counterregulatory hormone responses to hypoglycemia in normal and diabetic man. Diabetes 37: in press, 1987. 21 Gjedde A, and Crome C: Blood-brain glucose transfer: repression in chronic hyperglycemia. Science 214: 456–457, 1981. 22 McCall AL, Tornheim K, Flemming N, and Ruderman H: Brain transport and metabolism in chronic hypoglycemia. Diabetes 34 (Suppl 1): 37A, 1985. 23 Bolli G, DeFeo P, Compagnucci P, Cartechini MG, Angeletti G, Santeusanio F, Brunetti P, and Gerich J: Abnormal glucose counterregulation in insulin-dependent diabetes mellitus. Diabetes 32: 134–141, 1983. 24 Meneilly AS, Minaker RL, Young JB, Lansberg L, and Rowe JM: Counterregulatory responses to insulin-induced glucose reduction in the elderly. J Clin Endocrinol Metab 61: 178–182, 1982. 25 Amiel SA, Simonson DC, Sherwin RS, Lauritano AA, and Tamborlane WV: Exaggerated epinephrine responses to hypoglycemia: a possible mechanism for labile blood glucose in the young diabetic patient. J Pediatr, in press. 26 Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, and Tamborlane WV: Impaired insulin action in puberty: a contributing factor to poor diabetic control during adolescence. N Engl J Med 315: 215–219, 1986. 27 Felig P: The glucose-alanine cycle. Metabolism 22: 179–207, 1973. 28 Chiasson JL, Lilgenquist JE, Finger FE, and Lacy WW: Differential sensitivity of glycogenolysis and glucogenogenesis to insulin infusion in dogs. Diabetes 25: 283–291, 1976. 29 Rizza R, Mandarino L, and Gerich J.: Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am J Physiol 240: E630–E639, 1981. 30 Garber AJ, Cryer PE, Santiago JV, Haymond MW, Pagliara AS, and Kipnis DM: The role of adrenergic mechanisms in the substrate and hormonal response to insulin-induced hypoglycemia. J Clin Invest 58: 7–15, 1976. 31 Saccà L, Sherwin RS, Hendler R, and Felig P: Influence of continuous physiologic hyperinsulinemia on glucose kinetics and counterregulatory hormone responses in normal and diabetic humans. J Clin Invest 63: 849–857, 1979. 32 Glinsman WH, Hern EP, and Lynch A: Intrinsic regulation of glucose output by rat liver. Am J Physiol 216: 698–703, 1969. 33 Hansen I, Firth R, Haymond M, Cryer P, and Rizza R: The role of autoregulation of the hepatic glucose production in man's response to a physiological decrement in plasma glucose. Diabetes 35: 186–191, 1986. 34 Bolli G, DeFeo P, Perriollo G, DeCosmo S, Ventura M, Campbell P, Brunetti P, and Gerich J: Role of hepatic autoregulation in defense against hypoglycemia in humans. J Clin Invest 75: 1623–1631, 1985. 35 Axelrod J, and Weinschilboum R: Catecholamines. N Engl J Med 287: 237–242, 1972. 36 Service FJ, Nelson RL, Rubenstein AH, and Go VLW: Direct effect of insulin on secretion of insulin, glucagon, gastric inhibitory polypeptide, and gastrin during maintenance of normoglycemia. J Clin Endocrinol Metab 47: 488–493, 1978. 37 Rizza RA, Cryer PE, and Gerich JE: Role of glucagon, catecholamines and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha- and beta-blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia. J Clin Invest 64: 62–71, 1979. 38 Rizza RA, Haymond MW, Cryer PE, and Gerich JE: Differential effects of physiologic concentrations of epinephrine on glucose production and disposal in man. Am J Physiol 237: E356–E362, 1979. 39 Shamoon H, Hendler R, and Sherwin RS: Synergistic interactions among antiinsulin hormones in the pathogenesis of stress hyperglycemia in humans. J Clin Endocrinol Metab 52: 1236–1241, 1980. 40 Ferrannini E, DeFronzo RA, and Sherwin RS: Transient hepatic response to glucagon in man: role of insulin and hyperglycemia. Am J Physiol 242: E73–E81, 1982. 41 Saccà L, Gelfand RA, and Sherwin RS: Epinephrine-insulin interactions in humans: dissociation of glucose and branched chain amino acid uptake by skeletal muscle. Diabetes 35 (Suppl 1): 83A, 1986. 42 Cherrington AD, Williams PE, Shulman GI, and Lacy WW: Differential time course of glucagon's effect on glycogenolysis and gluconeogenesis in the conscious dog. Diabetes 30: 180–187, 1980. 43 Saccà L, Vigorito C, Cicala M, Corso G, and Sherwin RS: Role of gluconeogenesis in epinephrine-stimulated hepatic glucose production in humans. Am J Physiol 247: E294–E304, 1983. 44 Saccà L, Eigler N, Cryer PE, and Sherwin RS: Insulin antagonist effects of and glucagon in the dog. Am J Physiol 237: E487–E492, 1979. 45 Gerich JE, Cryer PE, and Rizza RA: Hormonal mechanisms in acute counterregulation: the relative roles of glucagon, epinephrine, norepinephrine, growth hormone and cortisol. Metabolism 29: 1165–1175, 1980. 46 Sherwin RS, Shulman GA, Hendler R, Walesky M, Belous A, and Tamborlane WV: Effect of growth hormone on oral glucose tolerance and circulating metabolic fuels in man. Diabetologia 24: 155–161, 1983. 47 Eigler N, Saccà L, and Sherwin RS: Synergistic interactions of physiologic increments of glucagon, epinephrine and cortisol in the dog: a model for stress-induced hyperglycemia. J Clin Invest 63: 114–123. 48 Press M, Tamborlane WV, and Sherwin RS: Importance of raised growth hormone levels in mediating the metabolic derangements of diabetes. N Engl J Med 310: 810–815, 1974. 49 Cherrington AD, Williams PE, and Harris MS: Relationship between the plasma glucose level and glucose uptake in the conscious dog. Metabolism 27: 787–791, 1978. 50 Rizza RA, Mandarino L, and Gerich JE: Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor defect of insulin action. J Clin Endocrinol Metab 54: 131–138, 1982. 51 Bratush-Marrain PR, Smith D, and DeFronzo RA: The effect of growth hormone on glucose metabolism and insulin secretion in man. J Clin Endocrinol Metab 55: 1648–1658, 1982. 52 Ferrannini E, Barrett EJ, Bevilacqua S, and DeFronzo RA: Effect of fatty acids on glucose production and utilization in man. J Clin Invest 72: 1737–1747, 1983. 53 Saccà L, Vigorito C, Cicala M, Ungaro B, and Sherwin RS: Mechanisms of epinephrine-induced glucose intolerance in normal humans. J Clin Invest 69: 284–293, 1982. 54 DeFronzo RA, Ferrannini E, Hendler R, Wahren J, and Felig P.: Influence of hyperinsulinemia, hyperglycemia, and the route of glucose administration on splanchnic glucose exchange. Proc Natl Acad Sci USA 75: 5173–5177, 1978. 55 Potter J, Clarke P, Gale EA, Dave SH, and Tattersall RB: Insulin-induced hypoglycemia in an accident and emergency department: the tip of an iceberg? Brit Med 285: 1180–1182, 1982. 56 Barnett AH, Leslie D, and Watkins RJ: Can insulin-treated diabetics be given beta-adrenergic blocking drugs? Brit Med J 282: 976–978, 1980. 57 Tchobroutsky G, Goldgewicht C, Papoz L, Weissbrod TP, Basdevant A, and Eschwege E: Hypoglycemic reactions in 319 insulin-treated diabetics. Diabetologia 21: 335, 1981. 58 Goldstein DE, England JD, and Hess R: A prospective study of symptomatic hypoglycemia in young diabetic patients. Diabetes Care 4: 601–605, 1981. 59 Caspari AF, and Ewing LD: Severe hypoglycemia in diabetic patients: frequence, causes prevention. Diabetes Care 8: 141–145, 1985. 60 Lauritzen T, Frost-Larsen K, Larsen H-W, and Deckert T: Steno Study Group. Effect of 1 year near-normal blood glucose levels on retinopathy in insulin-dependent diabetics. Lancet 1: 200–204, 1983. 61 The Kroc Collaborative Study Group. Blood glucose control and the evolution of diabetic retinopathy and albuminuria. A preliminary multicenter trial. N Engl J Med 311: 365–372, 1984. 62 The DCCT Research Group. Results of the feasibility phase of the Diabetes Control and Complications Trial (DCCT): glycemic control, follow-up the complications of therapy. Diabetes 1986; 35: Suppl 1: 3A. 63 Tang Fui SN, Pickup JC, Bending JJ, Collings ACT, Keen H, and Dalton N.: Hypoglycemia and counterregulation in insulin-dependent diabetic patients: a comparison of continuous subcutaneous insulin infusion and conventional insulin injection therapy. Diabetes Care 9: 221–227, 1986. 64 Bolli G, DeFeo P, Compagnucci P, Cartechinin MG, Angeletti G, Santeusanio F, Brunetti P, and Gerich JE: Abnormal glucose counterregulation in insulin-dependent diabetes mellitus. Interaction of antiinsulin antibodies and impaired glucagon secretion. Diabetes 32: 134–141, 1983. 65 Bolli GB, Dimitriadis GD, Pehling GB, Baker BA, Haymond MW, Cryer PE, and Gerich JE: Abnormal glucose counterregulation after subcutaneous insulin in insulin-dependent diabetes mellitus. N Engl J Med 310: 1706–1711, 1984. 66 Gerich JE, Langloisd M, Noacco C, Karam JH, and Forsham PH: Lack of a glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha-cell defect. Science 182: 171–173, 1973. 67 Wise JK, Hendler R, and Felig P: Evaluation of alpha-cell function by infusion of alanine in normal, diabetic and obese subjects. N Engl J Med 288: 487–490, 1973. 68 Unger RH, Aquilar Parada E, Muller WA, and Eisentraut AM.: Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest 49: 837–848, 1970. 69 Robertson RP, and Porte DP: The glucose receptor: a defective mechanism in diabetes mellitus distinct from the beta-adrenergic receptor. J Clin Invest 52: 870–876, 1973. 70 Unger R, Madison LL, and Muller WE: Abnormal alpha cell function in diabetes mellitus: response to insulin. Diabetes 21: 301–307, 1972. 71 Adamson U, Lins PE, Efendic S, Hamberger B, and Wajngot A: Impaired counterregulation of hypoglycemia in a group of insulin-dependent diabetics with recurrent episodes of severe hypoglycemia. Acta Med Scand 216: 215–222, 1984. 72 Guigliano D, Giannetti G, Di Pnto P, Cerciello T, Ceriello A, and D'Onofrio F: Normalisation by sodium salicylate of the impaired counterregulatory glucagon response to hypoglycemia in insulin-dependent diabetes: a possible role for endogenous prostaglandins D. Diabetes 34: 521–525, 1985. 73 Maher TD, Tanenberg RJ, Greenberg BZ, Hoffman JE, Doe RP, and Goetz PC: Lack of a glucagon response to hypoglycemia in diabetic autonomic neuropathy. Diabetes 26: 196–200, 1977. 74 Walter RM, Dudl RJ, Palmer JP, and Ensinck JW.: The effect of adrenergic blockade on the glucagon response to starvation and hypoglycemia in man. J Clin Invest 54: 1214–1220, 1974. 75 Palmer JP, and Ensick JW: Glucagon response to hypoglycemia in sympathectomised man. Diabetes 23 (Suppl 1): 324A, 1974. 76 Palmer J, Werner P, Hollander P, and Ensinck J: Evaluation of the control of glucagon secretion by the parasympathethic nervous system in man. Metabolism 28: 543–552, 1979. 77 Bloom SR, Vaughan NJA, and Russell RCG: Truncal vagotomy delays and diminishes the glucagon response to hypoglycaemia in normals. Lancet 2: 546–549, 1974. 78 Bolli G, Calabrese G, DeFeo P, Compagnucci P, Zaga G, Angeletti G, Cartechini MG, Santeusanio F, and Brunetti P: Lack of a glucagon response in glucose counterregulation in Type I (insulin-dependent) diabetics: absence of recovery after prolonged insulin therapy. Diabetologia 22: 100–105, 1982. 79 Shamoon H, Hendler R, and Sherwin RS: Altered responsiveness to cortisol, epinephrine and glucagon in insulin-infused juvenile onset diabetics: a mechanism for diabetic instability. Diabetes 29: 284–291, 1980. 80 DeFronzo RA, Hendler R, and Simonson D.: Insulin resistance is a prominent feature of insulin-dependent diabetes. Diabetes 31: 795–801, 1982. 81 Kleinbaum J, and Shammon H: Reduced counterregulation of hypoglycemia in insulin-dependent diabetes mellitus. Diabetes 32: 493–498, 1983. 82 White NH, Skor D, Cryer PE, Bier DM, Levandoski L, and Santiago JV: Identification of type I diabetic patients at increased risk for hypoglycemia during intensive therapy. N Engl J Med 308: 485–491, 1983. 83 DeFeo P, Bolli G, Perriollo G, de Cosmo S, Compagnucci P, Angeletti G, Santeusanio F, Gerich JE, Motolese M, and Brunetti P.: The adrenergic contribution to glucose counterregulation in Type I diabetes mellitus: dependency on A cell function and mediation through beta 2 adrenergic receptors. Diabetes 32: 887–893, 1983. 84 Hilstead J, Madsbad S, Krarup T, Sestoft L, Christensen NJ, Tronier B, and Galbo H: Hormonal, metabolic and cardiovascular responses to hypoglycemia in diabetic autonomic neuropathy. Diabetes 30: 626–633, 1981. 85 Hirsh BR, and Shamoon H: Defective epinephrine and growth hormone responses in Type I diabetes a stimulus specific. Diabetes 36: 20–26, 1987. 86 Hilsted J, Madsbad S, Karaup T, Tronier B, Galbo H, Sestoft L, and Schwartz TW: No response of pancreatic hormones to hypoglycemia in diabetic autonomic neuropathy. J Clin Endocrinol Metab 54: 815–819, 1982. 87 Tamborlane WV, Genel M, Sherwin RS, and Felig P: Restoration of normal lipid and amino acid metabolism in diabetic patients treated with a portable infusion pump. Lancet 1: 1258–1261, 1979. 88 Dunn F, Pietri A, and Raskin P: Plasma lipid and lipoprotein levels with continuous subcutaneous insulin infusion in Type I diabetes mellitus. Ann Int Med 95: 426–431, 1982. 89 Lopes-Virella M, Sherer G, Lees A, Wohlman H, Mayfield R, Sagel L, et al: Surface binding, internalization and degradation by cultured human fibroblasts of low density lipoproteins isolated Type I (insulin-dependent) diabetic patients: changes with metabolic control. Diabetologia 2: 430–436, 1982. 90 Tamborlane WV, Hintz RL, Bergman M, Genel M, Felig P, and Sherwin RS: Insulin infusion pump treatment of diabetics. Influence of improved metabolic control upon plasma somatomedin levels. N Engl J Med 305: 303–307, 1981. 91 White NH, Waltman SR, Krupin T, and Santiago JV: Reversal of abnormalities in ocular fluorometry in insulin-dependent diabetes after five to nine months of improved metabolic control. Diabetes 31: 80–85, 1982. 92 Viberti GC, Pickup JC, Jarrett RJ, and Keen H: Effect of control of blood glucose on urinary excretion of albumin and beta microglobulin in insulin-dependent diabetics. N Engl J Med 300: 638–641, 1979. 93 Unger RH: Meticulous control of diabetes: benefits, risks and precautions. Diabetes 31: 479–483, 1982. 94 Santiago JV, White NH, Skor DA, Levandoski LA, and Cryer PE: Defective glucose counterregulation limits the intensive therapy of insulin-dependent diabetes mellitus. Am J Physiol 247: E215–E220, 1984. 95 Simonson DC, Tamborlane WV, DeFronzo RA, and Sherwin RS: Intensive insulin therapy reduces the counterregulatory hormone responses to hypoglycemia in patients with Type I diabetes. Ann Int Med 103: 184–190, 1985. 96 Lager I, Blohme G, von Schenck H, and Smith U: Importance of glucose control for the recovery from hypoglycemia in insulin-dependent diabetics. Diabetes 31: 771–775, 1982. 97 Bolli G, DeFeo P, deCosmo S, Perriello G, Angeletti G, Ventura MR, Santeusanio F, Brunetti P, and Gerich JE: Effects of long-term optimization and short-term deterioration of glycemic control on glucose counterregulation in Type I diabetes mellitus. Diabetes 33: 394–400, 1984. 98 Amiel SA, Sherwin RS, and Tamborlane WV: Intensive insulin therapy lowers glucose thresholds for counterregulation: a risk factor for hypoglycemia in diabetes. Diabetes 35 (Suppl 1): 4A, 1986. 99 Amiel SA, Tamborlane WV, Simonson DC, and Sherwin RS: Defective glucose counterregulation after strict control of insulin-dependent diabetes mellitus. N Engl J Med 316: 1376–1383, 1987. Citing Literature Volume4, Issue1February 1988Pages 71-89 ReferencesRelatedInformation